A major study conducted in South Australia with almost 35000 participants has failed to show any discernible difference on herd immunity or throat carriage of Neisseria meningitidis.
The study was led by vaccinologist Professor Helen Marshall, who was pleased the vaccine afforded a high level of protection among participants, with no cases of meningococcal disease occuring during the study, compared with 12 cases in the same age group in the two years prior.
Alongside these findings, results of a UK study were published, estimating adjusted vaccine effectiveness to be 59% with a two-dose infant priming schedule plus a booster at 12 months of age since their publicly funded infant immunisation schedule began using the 4CMenB vaccine in 2015.
Read the full article here:
For further information about meningococcal vaccines, please refer to our Meningococcal disease and vaccines page